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ABSTRACT 
 
The routine approach for targeting nanoparticle delivery vehicles to cancer cells is by 
incorporating targeting ligands (e.g. antibodies or aptamers) to the surface of nanoparticles 
(NPs). Although targeting ligands are known to interact with specific receptors in the membranes 
of cancer cells, resulting in enhanced NP uptake, these functionalized NPs have an undesirable 
biodistribution and unfavorable targeting efficacy. Here we demonstrate a novel approach to 
target NPs to the cancer cells via click chemistry. Cancer cells are first metabolically labeled 
with an azide-modified monosaccharide (azidosugar). In the second step, NPs that are 
functionalized with highly-reactive cycloalkynes selectively bind to the cancer cells due to a 
spontaneous click reaction between the cycloalkynes on NP’s surfaces and the metabolically 
incorporated azide groups in the cell membranes. Our results show that HeLa and Chinese 
hamster ovary (CHO) cells are successfully labeled with azidosugars, and cycloalkyne-
functionalized silica NPs bind to the metabolically labeled cells via the click reaction. 
The click chemistry reaction was also used to study the effect of protein adsorption on active 
NP targeting. Upon exposure of NPs to the biological environment, proteins and other 
biomolecules bind to the NPs and cover their surfaces. This protein coating, which is called the 
protein corona, may reduce the targeting capability of functionalized NPs by screening their 
targeting ligands. Here we used cycloalkyne-functionalized silica NPs that can bind to the azide-
modified silicon substrates to study this effect. The results demonstrate that the formation of 
protein corona significantly decreased the conjugation of functionalized NPs to the substrate. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Cancer and Drug Delivery 
Cancer is one of the leading causes of death in the United States and many other parts of the 
word such that 25% of deaths in the United States are due to cancer.1 Among current approaches 
for cancer treatment, anti-cancer drugs can significantly inhibit the tumor growth, but they have 
undesired side effects, such as toxicity toward healthy tissues.  In addition to these side effects, 
multiple administrations of the anticancer drug are typically required to maintain an effective 
drug concentration in the body (Figure 1.1).  Consequently, new drug delivery approaches are 
required to overcome these obstacles.  
Nanoparticles are a promising delivery system for specifically targeting anticancer drugs to 
tumors, thereby reducing their detrimental side effects.2 Drug-loaded nanoparticles may have the 
ability to deliver drugs to a desired location in the body and release the drug over long periods of 
time with a maintained concentration. This would improve the therapeutic activity of the drug, 
reduce the number of required drug administrations, and yield a less invasive cancer treatment. 
 
Figure 1.1. Plot shows the drug concentration in the body as a function of time for a traditional 
drug delivery system (i.e., a pill or injection) and a controlled release system. The controlled 
release system maintains a constant drug concentration that is within the therapeutic window (the 
area between dashed lines). In contrast, for the traditional non-controlled drug delivery system, 
the drug concentration rapidly rises into toxic levels shortly after administration, and then drops 
to ineffective levels as the time interval increases, necessitating multiple administrations. 
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For targeting nanoparticles to cancer cells, nanoparticles should pass through spleen, liver 
and kidney filtration and diffuse to the tumor tissue. Passive targeting is a common tumor 
targeting approach that exploits the defective tumor vasculature that makes the blood vessels 
surrounding tumors more permeable than normal tissue, which is called the enhanced 
permeability and retention (EPR) effect.3 Thus, nanomaterials with a specific size range, around 
10 nm to 100 nm,3 can pass through this leaky vasculature and accumulate in tumor tissue 
(Figure 1.2).4 
 
 
Figure 1.2. Electron micrograph showing permeable structure of tumor blood vessels (Copyright 
(1998) National Academy of Sciences, U.S.A., Ref 4). 
 
An active nanoparticle targeting method has also been developed to increase the overall 
accumulation of nanoparticles in cancer cells in order to increase their therapeutic efficacy. For 
active targeting, the surface of nanoparticle is functionalized with small molecules, called 
targeting ligands (e.g. antibodies or aptamers), which selectively interact with receptors in the 
cancer cell’s plasma membrane, leading to nanoparticle’s uptake by the cancer cells (Figure 
1.3).2,5 Nanoparticles that are functionalized with active targeting ligands still exploit the EPR 
effect in order to penetrate into the tumor tissue, but their binding to the cancer cell’s surface is 
expected to enhance their uptake. Unfortunately, active targeting approaches seldom achieved 
significant improvements in targeting efficiency in vivo. A large fraction of the nanoparticles 
accumulate in the liver and spleen instead of the tumor,6 and the circulation time of nanoparticles 
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that are modified with targeting ligands is lower than unmodified nanoparticles.7 These factors 
prohibit the effective in vivo targeting of NP-ligand conjugates, resulting in an increased immune 
response and reduced anticancer efficacy.7 Thus, fundamental changes in the design of NPs for 
cancer targeting are urgently needed to overcome this unfavorable biodistribution. 
 
 
Figure 1.3. Passive and active targeting of nanoparticles to the tumor (Reprinted by permission 
from Macmillan Publishers Ltd: [Nature Nanotechnology] (Ref.2), copyright (2007)). 
 
1.2 Protein Corona 
When NPs are exposed to biological fluids within the in vivo environment, proteins and 
other biomolecules adsorb to their surface. The resulting protein coating, which is named the 
protein corona,8-10 is stable for several hours. Previous studies show that the protein corona can 
significantly influence NP’s uptake by the cells.  For example, Lesniak et al. have shown that the 
protein adsorption to the NPs’ surfaces decreases cellular uptake.11 A study of cellular uptake of 
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silica NPs in the presence and absence of the protein corona indicates the protein corona reduces 
cellular uptake and alters the NPs’ intracellular locations.12 The protein corona may also affect 
NPs targeting efficacy by a non-biological mechanism. When nanoparticles are functionalized 
with targeting ligands and applied in vivo, the proteins and biomolecules that absorb to the NP’s 
surface may cover the targeting ligands, preventing them from interacting with their target 
receptors in the plasma membranes of the cancer cells. The protein corona’s hindrance effect 
may lead to a low targeting yield for functionalized NPs in vivo. Thus, investigating this effect 
can help researchers to design more efficient targeted delivery methods. 
 
1.3 Click Chemistry and Metabolic Labeling of Glycans 
Glycans are oligosaccharide moieties attached to lipids and proteins. Glycans are involved in 
important biological processes such as cell adhesion13 and cancer progression.14 In fact, changes 
in glycans structure signal a change in the cell’s physiological condition.15 The ability to image 
glycans might permit detecting these health-related changes. However, unlike proteins, glycans 
cannot be labeled with genetically encoded probes, which renders the detection and imaging of 
glycans significantly more challenging. To address this challenge, Prof. C. R. Bertozzi and co-
workers have developed a two-step method for imaging glycans that is based on click 
chemistry.16,17 Click chemistry is defined as a modular reaction that occurs in very high yield and 
generates only inoffensive byproducts that are easily removed.18 For imaging glycans in cells, 
this click chemistry reaction must be compatible with physiological conditions.  Therefore, this 
reaction must be rapid and high-yielding when performed in an aqueous environment at 
physiological temperature.  In addition, the click chemistry reactants must be bioorthogonal, 
which means they selectively react with each other, but not with the chemical moieties that are 
native to biomolecules.  
The click reaction between azides and cycloalkynes has been widely used to label biological 
components.19 Because the azide group is small, mammalian cells can metabolize 
monosaccharides that are modified with an azide (X in Figure 1.4), and incorporate these 
modified sugars into their glycans.16,17 In the two-step glycan imaging method developed by 
Prof. C. R. Bertozzi and co-workers, the cells are first metabolically labeled with an azide-
modified sugar, which is called an azidosugar (Figure 1.4).16,17 In the second step, a click 
chemistry reaction occurs between the metabolically incorporated azidosugars on the cells and 
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reactive cycloalkyne moieties that are attached to fluorescent probes, which enables imaging the 
glycans with fluorescence microscopy.16,17 
 
Figure 1.4. Metabolic labeling of glycans on the cell membrane 
 
The most employed click reactions with azides include copper catalyzed cycloadditions with 
terminal alkynes, modified Staudinger ligations with phosphines, and strain-promoted 
cycloadditions with cyclooctynes (Scheme 1.1).19 Unfortunately, the copper catalyst that is 
required for the cycloaddition of azides with terminal alkynes is toxic to cells, which is 
undesirable for cell labeling experiments.19-21 The bioorthogonal reaction between azide group 
and phosphines, known as Staudinger ligation, is a popular copper-free click reaction that could 
be used in biological systems.22,23 However, the utility of this reaction for in vivo studies is 
limited by its slow reaction kinetics.19 Fortunately, the strain-promoted cycloaddition reaction 
between azides and cyclooctynes achieves the desired rapid reaction kinetics without the use of a 
toxic catalyst.19 Moreover, adding an electron-withdrawing fluorine to the cyclooctyne moiety 
drastically increases the rate of the cycloaddition with an azide.24,25 
In the past decade, the click chemistry reaction between an azide and a strained alkyne has 
been used to selectively label and image glycans in numerous reported studies.19 Here we 
summarize a few studies that are relevant to the subject of this thesis.  In a study carried out by 
the Bertozzi research group, glycans of a developing zebrafish were imaged by using a 
difluorinated cyclooctyne (DIFO).15 They have successfully detected differences in the cell-
surface expression of glycans, their intracellular trafficking, and tissue distribution via this 
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metabolic labeling and copper-free click chemistry approach.15 The Bertozzi group has also 
investigated the labeling efficiency as a function of cyclooctyne structure.26 In this study, mouse 
cells were metabolically labeled by the introduction of N-azidoacetylmannosamine 
(Ac4ManNAz), and then various cyclooctynes with different side groups were injected to the 
mice to investigate their labeling efficiency.26 The results revealed that although some 
cyclooctynes reacted with modified glycans on the cells surface, the amount of protein binding, 
which was influenced by the lipophilicity of the cyclooctyne,  reduced the targeting and labeling 
efficiency.26,27 Unfortunately, the synthesis of the stained cycloalkynes used in this study, such as 
DIFO, is very time consuming and involves numerous (>8) sequential reactions. To address this 
drawback, Dommerholt et al. developed a new cyclooctyne, called a bicyclononyne (BCN), 
which has sufficient reactivity toward azides for click reactions, can be synthesized in far fewer 
steps, and also has less protein binding affinity.27 
  
Scheme 1.1. Copper catalyzed cycloaddition reaction between an azide and a terminal alkyne 
(a), modified Staudinger ligation of an azide with a phosphine (b), and the strain-promoted 
cycloaddition of an azide with a cyclooctyne (c). 
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1.4 Objective of This Work 
The goal of this thesis is to demonstrate a new in vivo targeted drug delivery approach that 
exploits a click chemistry reaction to selectively bind functionalized NPs to metabolically 
labeled cancer cells. The overall approach is shown in Figure 1.5. In the first step, azidosugars 
conjugated to a cancer cell-specific targeting ligand (e.g., an aptamer or antibody that selectively 
binds to antigens on the surfaces of the cancer cells) will be used to deliver the azidosugars to the 
targeted cancer cells. Metabolism of the azidosugar results in its incorporation into the glycans 
that are abundant on the surface of the cancer cells.28 After metabolically labeling the cancer 
cells, but not healthy cells, with the azidosugars, NPs that are functionalized with BCN are 
injected in vivo.  The click reaction between the azide groups in the membranes of the cancer 
cells and the BCN moieties on the NPs’ surfaces are envisioned to cause the NPs to bind to the 
cancer cells, and then enter the cells through endocytosis. This approach is expected to avoid the 
unfavorable biodistribution that occurs in prior active targeting approaches for the following 
reasons. First, we hypothesize that NPs functionalized with cycloalkynes, such as BCN, do NOT 
raise any immunogenic issues as compared to NP-antibody or NP-aptamer conjugates because 
the BCN-functionalized NPs (BCN-NPs) do not contain foreign proteins or DNA fragments. In 
addition, more proteins bind to the surfaces of NPs functionalized with aptamer or antibody 
targeting ligands than to unmodified NPs, which can lead to their clearance by the mononuclear 
phagocyte system (MPS).7 In contrast, BCN is an organic molecule that is believed to have lower 
protein binding affinity than other cycloalkyne molecules,27 which may result in lower protein 
adsorption and longer circulation times. Overall, this combination of lower accumulation in the 
liver, spleen and kidneys combined with the enhanced uptake by endocytosis will result in a 
higher fraction of NPs accumulated in the tumor. 
 
Figure 1.5. Targeted metabolic labeling of cancer cells followed by in vivo “click chemistry” for 
cancer targeting and therapy. 
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Along the general goal explained above, Chapter 2 describes our progress in metabolically 
labeling cells with azidosugars, imaging labeled cells via click chemistry, and binding of BCN 
modified NPs to the labeled cells. The results show that HeLa and Chinese hamster ovary (CHO) 
cells can be metabolically labeled with azidosugars and imaged after a click reaction between the 
azide groups and BCN. In addition, we also demonstrated that fluorescent silica NPs that were 
functionalized with BCN selectively bound to the cells labeled with azidosugars, whereas no 
binding was observed on unlabeled cells. 
Chapter 3 describes a simple approach to investigate if protein corona affects the targeting 
yield of functionalized NPs. NPs functionalized with BCN become immobilized on substrates 
that are modified with azide group due to the click reaction between BCN and the azides. 
Protein-coated functionalized NPs and protein-free (pristine) functionalized NPs were incubated 
with the azide-modified wafers, and NP immobilization was assessed. Fluorescence microscopy 
and scanning electron microscopy (SEM) showed a high number of the pristine NPs were 
conjugated to the azide-modified substrates whereas few protein-coated NPs were attached to the 
substrates. These findings confirmed the hypothesis that the protein corona establishes a barrier 
that inhibits the interactions between the ligand and its target on a separate surface, and 
significantly reduces NP targeting efficiency. Finally, Chapter 4 explains conclusions and future 
directions. 
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CHAPTER 2. TOWARDS THE DEVELOPMENT OF CLICK CHEMISTRY-
MEDIATED NANOMEDICINE FOR CANCER CELL TARGETING  
  
Notes and Acknowledgements 
This chapter describes unpublished work. Portions of this work were supported by a Career 
Award at the Scientific Interface from the Burroughs Wellcome Fund (to M. L. Kraft) and NIH 
1R21CA152627 (to J. Cheng). V. Mirshafiee was funded by the NIH National Cancer Institute 
Alliance for Nanotechnology in Cancer Midwest Cancer Nanotechnology Training Center (M-
CNTC) Grant.  Li Tang assisted with NP synthesis, and Kaiyan Lou assisted with the syntheses 
of the click chemistry reagents. 
 
2.1 Introduction 
Here, we report our progress towards using click chemistry to direct the delivery of 
fluorescent silica nanoparticles to target cells. In this work, we focus on the click chemistry 
reaction between an azidosugar (Ac4GalNAz) and the strained cycloalkyne moiety, 
bicyclononyne (BCN). As discussed in the Chapter 1, this reaction was selected because it 
spontaneously occurs under physiological conditions in the absence of toxic copper reagents, and 
the synthesis of BCN is shorter than that of other reported strained cycloalkynes.27 We first 
confirmed the feasibility of using click chemistry for labeling live cells. After synthesis of 
azidosugar (Ac4GalNAz) and cycloalkyne (BCN), HeLa and Chinese hamster ovary (CHO) cells 
were cultured in the presence of azidosugar and incubated with fluorophore-cycloalkyne 
conjugate (RITC-BCN) to assess whether the cells were labeled through click chemistry. Next, 
we evaluated whether a click chemistry reaction could be used to label target cells with 
functionalized NPs. Fluorescent silica NPs were synthesized and functionalized with BCN. Then, 
CHO cells were metabolically labeled with the azidosugar, fixed, and incubated with 
functionalized NPs. Finally, the fixed cells were imaged with fluorescent microscope to evaluate 
NPs binding to the cells. 
 
2.2 Materials and Methods 
All the chemicals were purchased form Sigma-Aldrich unless otherwise noted. 
Bicyclononyne (BCN) 1 was synthesized as shown in Scheme 2.1 following previously reported 
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procedures.27 Ac4GalNAz 2 was synthesized as previously reported (Scheme 2.1).28 16% 
paraformaldehyde solution was purchased from Electron Microscopy Sciences. Fluorescent 
microscopy images were acquired using a Leica CTR 6000 and a Carl Zeiss LSM 700 confocal 
microscope.  
Scheme 2.1. Synthesis of bicyclononyne (BCN) and azidosugar (Ac4GalNAz). 
 
2.2.1 Synthesis of Rhodamine B isothiocyanate-bicyclononyne conjugate (RITC-BCN, 3) 
To a solution of BCN (3 mg, 0.009 mmol) in dimethylformamide (DMF) (1 mL) was added 
Rhodamine B isothiocyanate (5 mg, 0.01 mmol) and triethylamine (0.01 mL) and the reaction  
mixture was stirred overnight at rt (Scheme 2.2). The reaction mixture was then concentrated in 
vacuum and the product was used without further purification. 
 
Scheme 2.2. Synthesis of RITC-BCN conjugate. 
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2.2.2 Synthesis of fluorescent silica NPs 
Fluorescent silica NPs were prepared as previously reported.29 Briefly, 3-
aminopropyltrimethoxysilane (30 mg, 0.173 mmol) was added to Rhodamine B isothiocyanate 
(RITC) (17 mg, 0.032 mmol) in 1 mL ethanol with triethylamine (20 µL, 0.144 mmol). The 
reaction was stirred for 12 h at 50 °C in the dark. The solvent was evaporated under vacuum, and 
the crude RITC-silane was dissolved in methanol (10 mg/mL) and used without further 
purification. Tetraethyl orthosilicate (TEOS) (62.5 µL) was added to a mixture of methanol (1 
mL), deionized (DI) water (0.36 mL) and concentrated ammonia (0.08 mL). The mixture was 
stirred at 150 rpm for 2 h, RITC-silane solution (25 µL of 10 mg/mL methanol) was added to the 
mixture, and the solution was stirred at 150 rpm at rt for 12 h. To functionalize the resulting 
silica NPs with amine moieties, 3-aminopropyltrimethoxysilane (3 µL) and TEOS (1 µL) were 
added to the NP solution and the reaction was stirred for 12 h. NPs were collected by 
centrifugation and washed with ethanol three times. 
 
2.2.3 Synthesis of BCN-functionalized silica NPs (BCN-NPs) 
Scheme 2.3 summarizes the conjugation of BCN to the surface of the NPs. Silica NPs (11 
mg) were dispersed in a 10% solution of succinic anhydride in DMF, and stirred overnight at rt. 
The NPs were collected by centrifugation, and washed three times with DMF. The resulting 
carboxylic acid-functionalized NPs (2 mg) were dispersed in 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer (1.5 mL, 0.1 M, pH 6.8), and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (50 mg, 0.261 mmol) and N-hydroxysuccinimide (50 mg, 0.434 mmol) were added 
to the solution. The mixture was stirred for 25 min at rt. The NPs were collected by 
centrifugation, washed with DI water, and then dispersed in phosphate buffered saline (PBS) (1 
mL, pH 7.4). BCN (5 mg) in methanol (50 µL) was added to NP solution and the reaction was 
stirred overnight. The resulting BCN-NPs were collected by centrifugation, washed three times 
with methanol, and suspended in deionized (DI) water.30 
 
2.2.4 Cell culture 
HeLa and CHO (Chinese hamster ovary) cells were grown in eagle's minimal essential 
medium (DMEM) or Ham F12 media supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin in a 5% CO2 incubator at 37°C. 
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Scheme 2.3. Surface modification of silica NPs with BCN. 
 
2.2.5 Live cell labeling and imaging 
HeLa cells were seeded at a density of 20,000 cells per well in 1 mL DMEM with 10% FBS 
(HyClone Laboratories) on 4-well Nunc Lab-Tek Chambered Cover Glass microscopy slides 
(Fisher). Cells were incubated with 50 µM of Ac4GalNAz for 40 h at 37 °C. HeLa cells 
incubated without Ac4GalNAz served as negative controls. The cells were rinsed with media 
three times and each well was filled with 50 μM BCN-RITC (diluted from a 10 mM dimethyl 
sulfoxide (DMSO) stock solution) in media and incubated for 15 min at 37 °C. The cells were 
rinsed with PBS and imaged with a fluorescence microscope at ambient temperature. 
CHO cells were cultured at a density of 10,000 cells in 2 mL media on 35 mm plastic dish 
(Sarstedt). Cells were grown with Ac4GalNAz at 50 µM concentration for 3 days at 37 °C. The 
cells were rinsed with FACS buffer (PBS containing1% FBS) for three times and each well was 
filled with 5 μM BCN-RITC in FACS buffer and incubated for 5 min at 37 °C. Cells were 
washed with FACS buffer for four times and imaged under confocal microscope.31 
 
2.2.6 Labeling fixed CHO cells with fluorescent NPs 
CHO cells were cultured with Ac4GalNAz as described above. After three days, the media 
was removed and cells were washed with PBS and fixed with 4% paraformaldehyde (dilution of 
16% solution in PBS). The fixed cells were incubated with 100 µg of functionalized NPs (BCN-
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NPs) in PBS (1 mL) for 1 h, and then were washed with PBS five times. After that, the cells 
were imaged with fluorescence microscope. 
  
2.3 Results and Discussion 
First, we evaluated the feasibility of labeling live cells and imaging them with click 
chemistry. HeLa and CHO cells were grown in the presence of Ac4GalNAz (50 µM) in order to 
metabolically incorporate the azidosugar into the glycans on the cell surface (experimental cells).  
HeLa and CHO cells that were grown in the absence of Ac4GalNAz were used as a negative 
control.  Next, the experimental and negative control cells were treated with RITC-BCN. As 
shown in Figure 2.1.a and c, azidosugar-treated cells exhibited high fluorescence, which 
demonstrates the click chemistry reaction occurred between the metabolically incorporated cell 
surface azides and RITC-BCN.  In comparison, the negative control cells exhibited significantly 
weaker fluorescence, likely caused by the non-specific adsorption of RITC-BCN to the cells’ 
surfaces (Figure 2.1.b and d). 
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Figure 2.1. Fluorescence microscopy images of HeLa and CHO cells after incubation with 
RITC-BCN. (a and c) HeLa and CHO cells that were metabolically labeled with Ac4GalNAz 
exhibited strong fluorescence that indicated the RITC-BCN undergone a click chemistry reaction 
with the azides on the cell surface. (b and d) HeLa and CHO cells grown in the absence of 
Ac4GalNAz exhibited much weaker fluorescence that was likely caused by nonspecific 
adsorption of the dye to their surfaces. 
 
Having confirmed that metabolically incorporated cell surface azides were accessible for a 
click chemistry reaction, we next evaluated whether the click reaction targeted fluorescent silica 
NPs that were functionalized with BCN to bind to cells with metabolically incorporated 
azidosugars on their surfaces. CHO cells were metabolically labeled with Ac4GalNAz and fixed 
prior to incubation with the functionalized NPs. Fixation was used to exclude the possibility that 
the NPs were nonspecifically uptaken by the cells, thereby ensuring that only NP binding to the 
cells would be detected by fluorescence microscopy. The fluorescence microscopy images show 
20 µm 20 µm 
100 µm 100 µm 
a b 
c d 
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that NPs bound to the surfaces of the cells that were metabolically labeled with the azidosugars, 
but not to the cells that were not metabolically labeled with azidosugars (Figure 2.2).  
 
Figure 2.2. Bright field and fluorescence microscopy images of CHO cells treated with BCN-
NPs. (a and c) CHO cells cultured in the absence of Ac4GalNAz were not labeled with BCN-
functionalized NPs. (b and d) The high fluorescence intensity indicates the CHO cells that were 
metabolically labeled with Ac4GalNAz had BCN-functionalized NPs conjugated to their 
surfaces. 
 
These results confirm that the click chemistry reaction between the BCN on the NPs and the 
azidosugars on the cells’ surfaces can be used to selectively label target cells with NPs. Although 
metabolic labeling can be achieved in vitro by adding the azidosugar to the cell culture medium, 
subsequent work must be completed to enable the selective delivery of the azidosugar, and thus, 
metabolic labeling, of the target cancer cells in vivo. Promising approaches for achieving this 
goal are discussed in the Chapter 4.  
 
50 µm 50 µm 
a b 
c d 
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CHAPTER 3. PROTEIN CORONA SIGNIFICANTLY REDUCES ACTIVE 
TARGETING YIELD 
 
Notes and Acknowledgements 
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10.1039/C3CC37307J),32 and is reproduced by permission of The Royal Society of Chemistry. 
Portions of this work were carried out in the Metabolomics Center in the Roy J. Carver 
Biotechnology Center, Univ. of Ill., and the Frederick Seitz Materials Research Laboratory 
Central Facilities, Univ. of Ill., which is partially supported by the U.S. Department of Energy 
(DOE) under grants DEFG02-07ER46453 and DE-FG02-07ER46471. Portions of this work 
were supported by a Career Award at the Scientific Interface from the Burroughs Wellcome 
Fund (to MLK) and NIH 1R21CA152627 (to JC). VM was funded by the NIH National Cancer 
Institute Alliance for Nanotechnology in Cancer Midwest Cancer Nanotechnology Training 
Center (M-CNTC) Grant.  The authors thank Li Tang for assistance with NP synthesis and Qian 
Yin for zeta potential measurements. 
 
3.1 Introduction 
NPs are promising materials for the targeted delivery of therapeutic drugs to the desired site 
in the human body.8 One strategy to obtain a high targeting yield is to functionalize the surface 
of the NPs with targeting ligands (e.g. antibodies or aptamers) that enhance NP binding to 
receptors on the target cells and facilitate NP uptake by receptor-mediated endocytosis.33,34 In 
vitro results generally confirm the high capability of functionalized NPs for targeting to the 
desired cells. However, lower targeting yields and an unfavorable biodistribution (i.e., NP 
accumulation in the liver and spleen instead of the desired tumor tissue) is often observed in 
vivo.6  
The discrepancy between the in vitro and in vivo results is due, in part, to the adsorption of 
proteins and other biomolecules to the NP’s surface upon exposure to the biological medium in 
vivo.8-10 In contrast, the NP surface remains nearly pristine in the presence of the serum-free 
medium that is often used for in vitro studies of NP uptake.8 Therefore, cells in in vitro 
experiments that employ serum-free medium interact with the original NP surface, whereas cells 
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in vivo interact with the protein coating, which is called the protein corona.8-10 The presence of 
the protein corona on the NP, which is strongly related to the physicochemical properties of the 
NP and protein sources,7,35,36 is reported to alter the biodistribution, cellular uptake mechanism, 
and intracellular location of the NPs in vivo.6,12,37-39 In addition to these changes in biological 
phenomena, the protein corona may compromise the targeting efficiency of NPs that are 
functionalized with targeting ligands via a non-biological mechanism. Specifically, the protein 
corona surrounding the NP is hypothesized to hinder interactions between the NP’s ligands and 
their targets on the cell surface,6 though this mechanism has not been directly tested. Thus, the 
main aim of this work is to investigate whether the protein corona inhibits NP ligand binding to 
reactive moieties on a surface. 
To permit separating the protein corona’s effects on biological phenomena (i.e., uptake 
mechanism) from its potential ability to limit access to the targeting ligand, we selected a copper-
free click reaction between NPs functionalized with a strained cycloalkyne, BCN, and an azide 
on a silicon substrate as the model targeting reaction (Scheme 3.1).  
 
Scheme 3.1. A copper-free click reaction between the BCN moieties on the NPs and the azides 
on the modified silicon substrate was selected as the model targeting reaction. 
 
We prepared fluorescent silica NPs with diameters of 75 nm using the Stöber method29 and 
then conjugated BCN targeting ligands to the NP surface. Silicon substrates were modified with 
an azide-terminated self-assembled monolayer (SAM). We evaluated whether BCN-NP 
conjugation to the azide-functionalized substrates was reduced by the protein corona that results 
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from exposing the BCN-functionalized silica NPs (BCN-NPs) to biological fluids. We compared 
the conjugation of pristine BCN-NPs to those of BCN-NPs exposed to mediums that mimic in 
vitro culture conditions (i.e., medium with 10% serum) and the biological fluids present in vivo 
(i.e., 100% serum). Pristine BCN-NPs and BCN-NPs exposed to medium with 10% serum (10% 
serum corona BCN-NPs) or 100% serum (100% serum corona BCN-NPs) were incubated with 
azide-functionalized substrates, and then conjugation was assessed with fluorescence microscopy 
and SEM. 
Finally, liquid chromatography-mass spectrometry/mass spectrometry approach (LC-
MS/MS) was used to assess the compositions of the protein coronas on the BCN-NPs that 
resulted from exposure to mediums that mimic the in vitro (10% serum) or in vivo (100% serum) 
environments.  
 
3.2 Materials and Methods 
All the chemicals were purchased form Sigma-Aldrich unless otherwise noted. Silicon 
substrates (5 mm by 5 mm diced silicon wafers) were purchased from Ted Pella, Inc. PBS was 
purchased from Lonza. FBS was purchased from HyClone Laboratories. BCN 1 was synthesized 
as shown in Scheme 2.1 following previously reported procedures.27  11-
Azidoundecyltrimethoxysilane 3 was synthesized from 11-bromoundecyltrimethoxysilane 
(GelSet, Inc.) as previously reported.40  Sequencing Grade Trypsin was purchased from G-
Biosciences (St. Louis, MO). Fluorescent microscopy images were acquired using a Leica CTR 
6000. SEM images were acquired on a Hitachi S4800 high resolution SEM. X-ray photoelectron 
spectrometry (XPS) spectra were acquired on a Physical Electronics PHI 5400. Size 
measurements were acquired using a ZetaPlus dynamic light-scattering (DLS) detector 
(Brookhaven Instruments). Zeta potential was measured with a Malvern Zetasizer 3000 (Malvern 
Instruments). BCN-functionalized NPs were synthesized as it was reported in chapter 2. 
 
3.2.1 Modification of silicon substrates with an azide-terminated self-assembled monolayer 
(SAM)  
Silicon substrates (5 mm by 5 mm) were cleaned in a freshly prepared piranha solution 
(H2SO4/H2O2, 4:1) for 30 min. (Extreme caution must be used when cleaning with piranha 
solution.  Gloves, goggles, and face shield should be used for protection.) The substrates were 
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thoroughly rinsed in deionized (DI) water and air dried.  To functionalize the substrate with an 
azide-terminated SAM, the silicon substrates were immersed in a 70 °C solution of 11-
azidoundecyltrimethoxysilane in toluene (1:9 v/v) with a trace amount of water (1 drop) for 2 h 
with occasional stirring (Scheme 3.2).41 After cooling to rt, the substrates were sonicated in fresh 
toluene for 5 min, washed with acetone, dichloromethane, methanol and DI water, and air 
dried.42 XPS analysis of the substrates confirmed the presence of the terminal azides on the SAM 
(Figure 3.1).  
 
Scheme 3.2. Modification of silicon substratewith an azide-terminated SAM. 
 
Figure 3.1. XPS data of SAM-modified silicon substrates confirms the presence of terminal 
azides. The photoelectron spectra of the nitrogen 1s binding energies shows the two peaks at 400 
and 404 eV that are characteristic of azides.43 
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3.2.2 Preparation of hard corona NPs 
The adsorption of serum proteins to the BCN-NPs was probed by exposing the NPs to 
mediums containing 10% or 100% FBS. An aqueous solution of BCN-NPs (100 μL, 2 mg/mL in 
DI water) was mixed with 900 μL of FBS solution (10% FBS in PBS, or 100% FBS, 
respectively), and the solution was incubated at 37°C for 1 h. This incubation time was selected 
because it is reported to produce a protein corona with a relatively stable composition, and little 
change in composition occurs after 1 h.10  Each sample of BCN-NPs in the FBS solution was 
centrifuged at 10,000g for 30 min, the supernatant was carefully removed, and the protein-coated 
BCN-NPs were suspended in 500 μL of PBS. To ensure the excess (unbound or loosely bound) 
proteins were removed from the BCN-NP solution, which is critical for subsequent analysis of 
the protein composition of the hard corona on the BCN-NPs, the centrifugation process was 
repeated three times,  and then the BCN-NPs were dispersed in cold PBS. 
 
3.2.3 Size and zeta potential analysis.  
Measurements were made on pristine, 10% serum corona, and 100% serum corona BCN-
NPs that were dispersed in PBS at a concentration of 100 µg/mL. The results are summarized in 
Table 3.1. 
 Pristine 10% serum corona 
100% serum 
corona 
size (d, nm) 154 383 634 
polydispersity 
index 0.19 0.28 0.34 
zeta potential 
(mV) -18.9 -16.6 -7.9 
 
Table 3.1. Size (hydrodynamic diameter, d), size distribution (polydispersity index, PDI), and 
zeta potential of BCN-NPs in PBS, determined by DLS.  
 
3.2.4 Conjugation of BCN-NPs to silicon substrates 
For each type of BCN-NP (pristine BCN-NPs, 10% serum corona BCN-NPs, and 100% 
serum corona BCN-NPs), a NP solution (200 µg of NPs in 500 µL of PBS) was added to an 
azide-modified silicon substrate and incubated for 90 min at rt while stirring at 300 rpm. Non-
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specific BCN-NP binding was assessed by incubating a solution of pristine BCN-NPs (200 μg in 
500 μL PBS) in the presence of a substrate that was not functionalized with azides for 90 min at 
rt while stirring at 300 rpm. For all samples, the unconjugated NPs were removed by rinsing in 
DI water.  Then the samples were dried in ambient air, and conjugation was assessed by imaging 
with fluorescence microscopy and SEM. 
 
3.2.5 Statistical analysis of reduction in targeting efficiency 
The reduction in targeting efficiency due to protein adsorption was quantified by comparing 
the average numbers of (i) pristine BCN-NPs, (ii) 10% serum corona BCN-NPs, and (iii) 100% 
serum corona BCN-NPs on the 5 x 5 mm azide-functionalized substrates. As a negative control, 
the number of pristine BCN-NPs on the 5 x 5 mm azide-free substrates was also assessed. Using 
Image J, a threshold fluorescence intensity level that represented NPs within the mosaic of 
images of the substrate was set, and the number of pixels that exceeded this threshold was 
counted.  For each experimental condition, two 5 x 5 mm substrates were analyzed, and the 
average number of BCN-NPs was calculated. The conjugation efficiency of the BCN-NPs 
exposed to serum-containing medium was calculated by dividing the average number of 10 or 
100% serum corona BCN-NPs on the substrate by the average number of pristine BCN-NPs per 
substrate and multiplying the resulting fraction by 100.  The conjugation efficiency of the 10% 
and 100% serum corona BCN-NPs were 5% and 1%, respectively, that of the pristine BCN-NPs.  
Therefore, the targeting efficiency for the 10% and 100% serum corona BCN-NPs was 94 and 
99%, respectively, lower than that of the pristine BCN-NPs. 
 
3.2.6 Composition analysis of protein coronas on BCN-NPs with liquid chromatography-mass 
spectrometry/mass spectrometry (LC-MS/MS) 
The BCN-NPs exposed to mediums containing 10% or 100% FBS were collected by 
centrifugation at 20,000g for 10 min, and the pellet was resuspended in 25 of Sequencing Grade 
Trypsin (25 μL, 12.5 ng/μL in 25 mM ammonium bicarbonate), and digested using a CEM 
Discover Microwave Digestor (Mathews, NC) for 15 min at 55 °C (70W).  Digestion was 
stopped by the addition of 200 μL of an acetonitrile/water/formic acid (50:45:5 v/v/v) solution. 
The solvents were removed using a Thermo SpeedVac, and the residue was dissolved in 13 μL of 
aqueous acetonitrile (5% acetonitrile) containing 0.1% formic acid.  Samples (10 μL) were 
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analyzed by LC-MS/MS performed on a Waters quadrupole time-of-flight mass spectrometer 
(Q-ToF) connected to a Waters nanoAcquity UPLC.  LC was performed on a Waters Atlantis C-
18 column (0.03 mm particle, 0.075 mm x 150 mm) using a flow rate of 250 nL/min.  Peptides 
were eluted using a linear gradient of aqueous acetonitrile (0-60% acetonitrile) containing 0.1% 
formic acid in 240 min.  The mass spectrometer was set for data dependent acquisition, and 
MS/MS was performed on the most abundant four peaks detected at any given time.  Data were 
analyzed using the Waters Protein Lynx Global Server 2.2.5, Mascot (Matrix Sciences) and 
Blasted against NCBI NR database specific for Bostaurus. The normalized percentage of spectral 
counts detected by LC-MS/MS for protein k (NpSpCk) was calculated according to Equation 1.9 
 
 
 
3.3 Results and Discussion 
The fluorescence microscopy images of substrates incubated with pristine and protein coated 
BCN-NPs are shown in Figure 3.2. Experiments in which pristine BCN-NPs were incubated with 
azide-free substrates confirmed that non-specific BCN-NP binding to the substrate was 
insignificant (Figure 3.2a). The fluorescence microscopy images show a high number of the 
pristine BCN-NPs were conjugated to the azide-functionalized substrate (Figure 3.2b). In 
contrast, fluorescence microscopy showed few 10% or 100% serum corona BCN-NPs had 
attached to the azide-functionalized substrates (Figure 3.2c and d). Quantitative analysis 
indicated that the number of conjugated NPs, and therefore the targeting efficiencies for the 10% 
and 100% serum corona BCN-NPs were lower than that of the pristine BCN-NPs by 94 and 
99%, respectively. SEM imaging confirmed these fluorescence microscopy results. The SEM 
images show numerous pristine BCN-NPs, but very few 10% or 100% serum corona BCN-NPs 
conjugated to the azide-functionalized substrates (Figures 3.3). These findings indicate the 
protein corona inhibits the NP’s targeting capability. 
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Figure 3.2. Fluorescence microscopy images of 5 mm by 5 mm silicon substrates after 
incubation with pristine BCN-NPs and those coated with a protein corona. (a) Little non-specific 
binding of pristine BCN-NPs to the azide-free substrate occurred. (b) Numerous pristine BCN-
NPs were conjugated to the azide-functionalized substrate. (c and d) Few10% (c) or 100% (d) 
corona BCN-NPs were visible on the azide-functionalized substrates. Arrows designate 
individual NPs. 
 
Characterization of the BCN-NPs in terms of size and zeta potential indicated that exposing 
the BCN-NPs to medium containing 10% or 100% serum increased their size, but only slightly 
decreased their negative charge (Table 3.1).  The increase in size upon exposure to serum-
containing media reflects formation of the protein corona as well as larger protein-NP 
complexes.44 The slight decrease in negative charge is due to screening of the negatively charged 
surface of the silica NP by the protein corona, and should not drastically alter the interactions 
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between the substrate and the BCN-NPs in these experiments. Although NP uptake by cells is 
very size-dependent,7 we do not expect that the approximately two-fold increase in BCN-NP 
diameter that occurred after exposure to 10% serum medium is the primary cause of the ~94% 
reduction in targeting efficiency we observed under these conditions. Therefore, the protein 
corona-induced inhibition of NP targeting capability we observed in this system was mainly 
caused by screening of the interactions between the NP’s targeting ligands and their reactive 
partners on the substrate. 
 
Figure 3.3. SEM images of silicon substrates modified with azide-terminated SAMs after 
incubation with pristine BCN-functionalized NPs. 
 
The composition of protein corona on the BCN-NPs was assessed using a liquid 
chromatography-mass spectrometry/mass spectrometry approach (LC-MS/MS). A 
comprehensive list of the proteins detected in the coronas on the 10% and 100% serum corona 
BCN-NPs are listed in Table 3.2. Evaluation of the normalized abundances of proteins within a 
specific molecular weight range (Figure 3.4) indicated that ≥88% of the proteins in the coronas 
on the BCN-NPs exposed to either serum-containing medium had a molecular weight below 30 
kDa. Despite their relatively low molecular weights, these proteins established a shell that 
significantly reduced the BCN targeting ligand’s ability to react with the azides on the surface. 
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Although Table 3.2 shows that the proportions of the different proteins within each of the two 
coronas differed, the proportions of proteins with a specific molecular weight range, and the 
reduction in NP conjugation were very similar. Thus, the protein’s molecular weight is the main 
factor correlating its propensity to adsorb to the NP and obstruct its targeting ligands. 
 
 
Molecular 
Weight (Da) 
 
Protein Name 
NpSpC 
10% 
serum 
corona 
100% 
serum 
corona 
451,342 dynein, axonemal, heavy chain 5 0.03 0 
248,286 factor V 0.32 0 
91,157 plasminogen precursor 0.19 0 
90,229 BR serine/threonine kinase 0 0.13 
85,836 integrin beta-6 precursor 0 0.19 
71,659 E3 SUMO-protein ligase PIAS1 0 0.18 
68,543 alpha-fetoprotein precursor 0.31 0.41 
66,088 serum albumin 0.41 1.12 
53,541 vitronectin 0.30 0 
48,427 kininogen I precursor 0.28 0 
48,118 kininogen II precursor 0 0.62 
46,075 alpha-1-antiproteinase precursor 0.98 1.73 
35,847 apolipoprotein E 2.41 0 
30,253 apolipoprotein A-I precursor 6.05 5.96 
15,849 hemoglobin fetal subunit beta 18.54 12.34 
15,044 Chain A, A Novel Allosteric Mechanism In Haemoglobin 32.25 47.28 
12,544 60S ribosomal protein L35a 0.89 0 
11,195 apolipoprotein A-II precursor 16.27 10.19 
2,337 fetuin 20.74 19.91 
 
Table 3.2. Comprehensive list of normalized percentage of each protein identified by LC-
MS/MS in the hard coronas on the BCN-NPs that were incubated for 1 h in medium containing 
10% and 100% FBS. 
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Figure 3.4. Normalized spectral counts (NpSpC) of proteins with the specified range of 
molecular weights detected in the hard coronas on the BCN-NPs incubated for 1 h in medium 
containing 10% and 100% FBS. 
 
Altogether, this study confirms the hypothesis that the protein corona establishes a barrier 
that screens the interactions between the ligand and its target on a separate surface (i.e., the cell 
membrane), thereby significantly reducing NP targeting efficiency as compared to NPs with 
pristine surfaces. We found that BCN-NP exposure to medium that contained as little as 10% 
serum, which is the typical serum concentration used for mammalian cell culture, resulted in the 
formation of a protein corona that significantly inhibited the model targeting reaction we studied. 
Our results imply that, in addition to NP clearance from the body (i.e., unfavorable 
biodistribution), screening of the targeting ligand by the protein corona that forms upon NP 
exposure to biological fluids contributes to the lower the NP targeting efficiencies attained in 
vivo than in vitro. Given that protein absorption to the NP surface cannot be prevented, as even 
modification of NPs with polyethylene glycol (PEG) reduces, but does not prevent, protein 
absorption,45 screening of the NP’s targeting ligand due to protein absorption must be considered 
when designing NPs for targeted drug delivery. Because the click chemistry reaction between 
BCN-NPs and the azide-functionalized surfaces used in this study enables separating the protein 
corona’s ability to obstruct the targeting ligand from its effects on biological phenomena, this 
approach may simplify assessing the extent that NPs with various surface modifications are 
screened by the protein corona. We expect that increased consideration of targeting ligand 
screening by the protein corona that surrounds the NP will help to improve the efficiency of NP 
uptake in vivo. 
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CHAPTER 4. CONCLUSIONS AND FUTURE DIRECTIONS 
 
To selectively deliver anti-cancer drugs to tumors, various NPs have been developed and 
their surface have been functionalized with targeting ligands that can bind to the receptors on the 
cancer cell membrane. Despite the initial expectation that the targeting ligands on the NPs would 
significantly increase in in vivo targeting efficiency, this approach did not considerably improve 
NP uptake by cancer cells. Instead, a large fraction of functionalized NPs typically accumulate in 
the liver and spleen. To address this challenge, we have designed a new targeting approach that 
involves metabolic cell labeling and click chemistry. In this approach, a saccharide derivative 
modified with an azide group (azidosugar) is metabolically incorporated into the glycans on the 
cancer cell membrane. Then, NPs that are functionalized with a reactive cycloalkyne, BCN, 
would be added to the cells. Through the spontaneous click reaction between the azide groups 
and bicyclononynes, the NPs would bind to the cancer cell membrane, which leads to their 
uptake via endocytosis. In this thesis, we demonstrated that HeLa and CHO cells could be 
metabolically labeled with an azidosugar and imaged by detection of fluorophore -BCN 
conjugate attached to the cell surface via a click chemistry reaction. In addition, we showed that 
NPs functionalized with BCN selectively bound to CHO cells that were metabolically labeled 
with the azidosugar, while there was no binding for cells that had not been metabolically labeled. 
Altogether, these results suggest that the proposed click chemistry approach will enable targeting 
NPs to metabolically labeled cells. 
To use this approach for in vivo targeting, only the cancer cells should have metabolically 
incorporated azidosugars on their surfaces. Thus, the azidosugars need to be selectively delivered 
to the cancer cells, but not healthy cells, prior to the administration of BCN-functionalized NPs. 
The future direction to achieve this aim is to conjugate the azidosugar to a targeting ligand, such 
as an antibody or aptamer, which selectively binds to the cancer cells. This is expected to 
increase the conjugate uptake by the cancer cells, and subsequent metabolic incorporation of the 
azidosugar into the glycans on the cancer cells’ surfaces. After the cancer cells are selectively 
labeled, BCN-functionalized NPs would be administered and their targeting efficiency would be 
evaluated.      
To obtain a desirable targeting efficiency for functionalized NPs, the targeting ligands on the 
NP’s surface must be accessible for interaction with the receptors on the cell membrane. 
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However, upon exposure to the biological environment, the NPs become covered with proteins 
and biomolecules. By using a click reaction as the model targeting reaction, we showed that this 
protein coating, called the protein corona, established a barrier that screened the targeting ligand, 
BCN, and prevented it from interacting with its azide targets on a silicon substrate (Figure 4.1). 
These results suggest that in addition to NP clearance from the body, the protein corona also 
contributes to the low targeting yields obtained in many in vivo studies. 
    
 
Figure 4.1. Simplified schematic of protein corona-induced screening of NP targeting ligands, 
which reduces targeted NP delivery. The protein corona covers the targeting ligands on the NP, 
preventing the ligands from binding to their targets on a separate surface (i.e., a cell). 
 
The click chemistry reaction between BCN-functionalized NPs and azides on a silicon 
surface provides a simple approach to assess the extent of targeting ligand screening. However, a 
cell-based platform would be required to assess the changes in biological phenomena that are 
induced by the protein corona, and how its composition may change as the NPs are trafficked 
through the endocytic compartments.46,47 Alternatively, one might exploit the protein corona as a 
targeting ligand.6,48 For example, the high vitronectin content in the protein corona of cationic 
lipid/DNA complexes enhances targeting to MDA-MB- 435S cancer cells, a cell line derived 
from M14 melanoma cells, that overexpress the two major vitronectin receptors, αβν3 and αβν5 
integrins.48 Overall, we expect that increased consideration of targeting ligand screening by the 
protein corona that surrounds the NP will help to improve the efficiency of NP uptake in vivo. 
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